Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
2 recherche sur le mot-clé 'probiotic'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Probiotic intervention in young children with autism spectrum disorder in Taiwan: A randomized, double-blinded, placebo-controlled trial / Jia-En WANG ; Fang-Ju SUN ; Yu-Hsin HUANG ; Hui-Ju CHEN in Research in Autism Spectrum Disorders, 109 (November 2023)
[article]
Titre : Probiotic intervention in young children with autism spectrum disorder in Taiwan: A randomized, double-blinded, placebo-controlled trial Type de document : Texte imprimé et/ou numérique Auteurs : Jia-En WANG, Auteur ; Fang-Ju SUN, Auteur ; Yu-Hsin HUANG, Auteur ; Hui-Ju CHEN, Auteur Article en page(s) : 102256 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder (ASD) Preschool Probiotic Psychobiotic Anxious/depressed Index. décimale : PER Périodiques Résumé : Background The impact of psychobiotics on ASD is unclear. Method In this double-blinded, randomized, placebo-controlled trial, 86 children (aged 2.5-7 years) with ASD were recruited and assigned randomly to either the probiotic or placebo group to explore the effects of the probiotic Lactobacillus plantarum PS128 (PS128). During the first 2 months of the study, the children received either the probiotic or placebo. After that, all of the children received PS128 for 2 more months. We categorized individuals who took PS128 for the entire 4-month duration as the "PS128 early use group" (E group), while those who initially received the placebo for 2 months and then took PS128 for the subsequent 2 months were classified as the "PS128 late use group" (L group). Results After adjusting for possible confounders, the results showed that the anxious/depressed subscale score of the Achenbach System of Empirically Based Assessment significantly improved in the E group after the first 2-month intervention (P = 0.044) when compared to the L group. In the subsequent 2 months, the L group showed a significant improvement in this subscale (P = 0.017). While the improvement observed during the first two months was not sustained on average in the E group from V2 to V3, this variability can be attributed to the influence of an outlier. Upon analyzing the hyperactivity subscale of the Attention-Deficit/Hyperactivity Disorder Test, no significant differences were found across multiple time points. Conclusions The results support that PS128 has beneficial effects on behavioral and emotional problems in young children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2023.102256 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=517
in Research in Autism Spectrum Disorders > 109 (November 2023) . - 102256[article] Probiotic intervention in young children with autism spectrum disorder in Taiwan: A randomized, double-blinded, placebo-controlled trial [Texte imprimé et/ou numérique] / Jia-En WANG, Auteur ; Fang-Ju SUN, Auteur ; Yu-Hsin HUANG, Auteur ; Hui-Ju CHEN, Auteur . - 102256.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 109 (November 2023) . - 102256
Mots-clés : Autism spectrum disorder (ASD) Preschool Probiotic Psychobiotic Anxious/depressed Index. décimale : PER Périodiques Résumé : Background The impact of psychobiotics on ASD is unclear. Method In this double-blinded, randomized, placebo-controlled trial, 86 children (aged 2.5-7 years) with ASD were recruited and assigned randomly to either the probiotic or placebo group to explore the effects of the probiotic Lactobacillus plantarum PS128 (PS128). During the first 2 months of the study, the children received either the probiotic or placebo. After that, all of the children received PS128 for 2 more months. We categorized individuals who took PS128 for the entire 4-month duration as the "PS128 early use group" (E group), while those who initially received the placebo for 2 months and then took PS128 for the subsequent 2 months were classified as the "PS128 late use group" (L group). Results After adjusting for possible confounders, the results showed that the anxious/depressed subscale score of the Achenbach System of Empirically Based Assessment significantly improved in the E group after the first 2-month intervention (P = 0.044) when compared to the L group. In the subsequent 2 months, the L group showed a significant improvement in this subscale (P = 0.017). While the improvement observed during the first two months was not sustained on average in the E group from V2 to V3, this variability can be attributed to the influence of an outlier. Upon analyzing the hyperactivity subscale of the Attention-Deficit/Hyperactivity Disorder Test, no significant differences were found across multiple time points. Conclusions The results support that PS128 has beneficial effects on behavioral and emotional problems in young children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2023.102256 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=517 Probiotics, prebiotics, synbiotics, and fecal microbiota transplantation in the treatment of behavioral symptoms of autism spectrum disorder: A systematic review / Q. TAN in Autism Research, 14-9 (September 2021)
[article]
Titre : Probiotics, prebiotics, synbiotics, and fecal microbiota transplantation in the treatment of behavioral symptoms of autism spectrum disorder: A systematic review Type de document : Texte imprimé et/ou numérique Auteurs : Q. TAN, Auteur ; C. E. ORSSO, Auteur ; E. C. DEEHAN, Auteur ; J. Y. KUNG, Auteur ; H. M. TUN, Auteur ; E. WINE, Auteur ; K. L. MADSEN, Auteur ; Lonnie ZWAIGENBAUM, Auteur ; A. M. HAQQ, Auteur Article en page(s) : p.1820-1836 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/therapy Behavioral Symptoms Fecal Microbiota Transplantation Gastrointestinal Microbiome Humans Prebiotics Probiotics/therapeutic use Randomized Controlled Trials as Topic Synbiotics autism spectrum disorder fecal microbiota transplant gut microbiota prebiotic probiotic synbiotic Index. décimale : PER Périodiques Résumé : The emerging role of a microbiota-gut-brain axis in autism spectrum disorder (ASD) suggests that modulating gut microbial composition may offer a tractable approach to addressing the lifelong challenges of ASD. The aim of this systematic review was to provide an overview and critically evaluate the current evidence on the efficacy and safety of probiotic, prebiotic, synbiotic, and fecal microbiota transplantation therapies for core and co-occurring behavioral symptoms in individuals with ASD. Comprehensive searches of MEDLINE, EMBASE, Scopus, Web of Science Core Collection, Cochrane Library, and Google Scholar were performed from inception to March 5, 2020, and two update searches were completed on October 25, 2020, and April 22, 2021, respectively. A total of 4306 publications were identified, of which 14 articles met the inclusion criteria. Data were extracted independently by two reviewers using a preconstructed form. Results of probiotic studies do not confirm the supposed beneficial effect of probiotics on ASD, whereas prebiotics and synbiotic combinations appear to be efficacious in selective behavioral symptoms. Evidence of the efficacy of fecal microbiota transplantation in ASD is still scarce but supports further research. Overall, the current evidence base to suggest beneficial effects of these modalities in ASD is limited and inconclusive. More clinical trials are currently looking at the use of microbial-based therapies in ASD. With a robust double-blind randomized controlled protocol to investigate the efficacy, these trials should provide significant and definitive results. LAY SUMMARY: There is a link between altered gut bacteria and autism spectrum disorder. Some people believe that modulating bacterial composition in the gut may help reduce autism symptoms, but evidence from human studies suggesting beneficial effects of probiotic, prebiotic, and combination thereof as well as fecal transplants in autism spectrum disorder is limited and inconclusive. Current data should not encourage use of these modalities. Further clinical studies are needed. En ligne : http://dx.doi.org/10.1002/aur.2560 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449
in Autism Research > 14-9 (September 2021) . - p.1820-1836[article] Probiotics, prebiotics, synbiotics, and fecal microbiota transplantation in the treatment of behavioral symptoms of autism spectrum disorder: A systematic review [Texte imprimé et/ou numérique] / Q. TAN, Auteur ; C. E. ORSSO, Auteur ; E. C. DEEHAN, Auteur ; J. Y. KUNG, Auteur ; H. M. TUN, Auteur ; E. WINE, Auteur ; K. L. MADSEN, Auteur ; Lonnie ZWAIGENBAUM, Auteur ; A. M. HAQQ, Auteur . - p.1820-1836.
Langues : Anglais (eng)
in Autism Research > 14-9 (September 2021) . - p.1820-1836
Mots-clés : Autism Spectrum Disorder/therapy Behavioral Symptoms Fecal Microbiota Transplantation Gastrointestinal Microbiome Humans Prebiotics Probiotics/therapeutic use Randomized Controlled Trials as Topic Synbiotics autism spectrum disorder fecal microbiota transplant gut microbiota prebiotic probiotic synbiotic Index. décimale : PER Périodiques Résumé : The emerging role of a microbiota-gut-brain axis in autism spectrum disorder (ASD) suggests that modulating gut microbial composition may offer a tractable approach to addressing the lifelong challenges of ASD. The aim of this systematic review was to provide an overview and critically evaluate the current evidence on the efficacy and safety of probiotic, prebiotic, synbiotic, and fecal microbiota transplantation therapies for core and co-occurring behavioral symptoms in individuals with ASD. Comprehensive searches of MEDLINE, EMBASE, Scopus, Web of Science Core Collection, Cochrane Library, and Google Scholar were performed from inception to March 5, 2020, and two update searches were completed on October 25, 2020, and April 22, 2021, respectively. A total of 4306 publications were identified, of which 14 articles met the inclusion criteria. Data were extracted independently by two reviewers using a preconstructed form. Results of probiotic studies do not confirm the supposed beneficial effect of probiotics on ASD, whereas prebiotics and synbiotic combinations appear to be efficacious in selective behavioral symptoms. Evidence of the efficacy of fecal microbiota transplantation in ASD is still scarce but supports further research. Overall, the current evidence base to suggest beneficial effects of these modalities in ASD is limited and inconclusive. More clinical trials are currently looking at the use of microbial-based therapies in ASD. With a robust double-blind randomized controlled protocol to investigate the efficacy, these trials should provide significant and definitive results. LAY SUMMARY: There is a link between altered gut bacteria and autism spectrum disorder. Some people believe that modulating bacterial composition in the gut may help reduce autism symptoms, but evidence from human studies suggesting beneficial effects of probiotic, prebiotic, and combination thereof as well as fecal transplants in autism spectrum disorder is limited and inconclusive. Current data should not encourage use of these modalities. Further clinical studies are needed. En ligne : http://dx.doi.org/10.1002/aur.2560 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449